Consolidated Statements of Operations (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended		9 Months Ended
	Sep. 30, 2013	Sep. 30, 2012	Sep. 30, 2013	Sep. 30, 2012
Income Statement [Abstract]
Net sales	$ 15,300	$ 13,645	$ 46,633	$ 41,934
Cost of sales	4,584	3,630	13,474	11,504
Gross profit	10,716	10,015	33,159	30,430
Sales and marketing	5,205	4,911	16,278	15,310
General and administrative	3,282	2,892	9,231	8,277
Research and development	1,300	1,261	3,841	3,531
(Gain) loss on divestitures		(50)		2
Medical device excise tax	153		463
Total operating expenses	9,940	9,014	29,813	27,120
Income from operations	776	1,001	3,346	3,310
Other income (expense):
Interest income	1	47	4	68
Interest expense	(6)		(18)
Foreign currency loss	14	7	(102)	(240)
Income before income taxes	785	1,055	3,230	3,138
Provision for income taxes	64	392	774	1,265
Net income	$ 721	$ 663	$ 2,456	$ 1,873
Earnings per share of common stock:
Basic	$ 0.05	$ 0.04	$ 0.16	$ 0.12
Diluted	$ 0.05	$ 0.04	$ 0.16	$ 0.12
Weighted-average shares outstanding:
Basic	15,339	15,130	15,262	15,208
Diluted	15,780	15,605	15,707	15,654
Cash dividends declared per common share	$ 0.030	$ 0.025	$ 0.090	$ 0.075